Diagnostic moléculaire des tumeurs solides 55
22. Van Cutsem E, Sobrero AF, Siena S, et al. (2012) Phase III CORRECT trial of regorafenib
in metastatic colorectal cancer (mCRC). ASCO Annual Meeting, Chicago, 01-05 juin
23. Van Cutsem E, Tabernero J, Lakomy R, et al. (2012) Addition of Aflibercept to Fluorouracil,
Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients
With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen.
J Clin Oncol 30: 3499-506
24. Tonon G, Wong KK, Maulik G, et al. (2005) High-resolution genomic profiles of human
lung cancer. Proc Natl Acad Sci U S A 102: 9625-30
25. Ding L, Getz G, Wheeler DA, et al. (2008) Somatic mutations affect key pathways in lung
l l
adenocarcinoma. Nature 455: 1069-75
26. Rauch TA, Zhong X, Wu X, et al. (2008) High-resolution mapping of DNA hypermethylation
and hypomethylation in lung cancer. Proc Natl Acad Sci U S A 105: 252-7
27. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet
Oncol 12: 175-80
28. Tang X, Shigematsu H, Bekele BN, et al. (2005) EGFR tyrosine kinase domain mutations
l l
are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer
Res 65: 7568-72
29. Kobayashi S, Boggon TJ, Dayaram T, et al. (2005) EGFR mutation and resistance of
l l
non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-92
30. Massarelli E, Varella-Garcia M, Tang X, et al. (2007) KRAS mutation is an important
l l
predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase
inhibitors in non-small-cell lung cancer. Clin Cancer Res 13: 2890-6
31. Soda M, Choi YL, Enomoto M, et al. (2007) Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature 448: 561-6
32. Shaw AT, Yeap BY, Mino-Kenudson M, et al. (2009) Clinical features and outcome
of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:
4247-53
33. Shaw AT, Yeap BY, Solomon BJ, et al. (2011) Effect of crizotinib on overall survival in
l l
patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a
retrospective analysis. Lancet Oncol 12: 1004-12
34. Bergethon K, Shaw AT, Ou SH, et al. (2012) ROS1 rearrangements define a unique
l l
molecular class of lung cancers. J Clin Oncol 30: 863-70
35. Stephens P, Hunter C, Bignell G, et al. (2004) Lung cancer: intragenic ERBB2 kinase
l l
mutations in tumours. Nature 431: 525-6
36. Arcila ME, Chaft JE, Nafa K, et al. (2012) Prevalence, clinicopathologic associations, and
l l
molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Clin Cancer Res 18: 4910-8
37. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. (2005) Increased HER2 gene copy
l l
number is associated with response to gefitinib therapy in epidermal growth factor
receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23: 5007-18
38. Paik PK, Arcila ME, Fara M, et al. (2011) Clinical characteristics of patients with lung
l l
adenocarcinomas harboring BRAF mutations. J Clin Oncol 29: 2046-51
39. Yamamoto H, Shigematsu H, Nomura M, et al. (2008) PIK3CA mutations and copy
number gains in human lung cancers. Cancer Res 68: 6913-21
40. Cappuzzo F, Marchetti A, Skokan M, et al. (2009) Increased MET gene copy number
negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin
Oncol 27: 1667-74
41. Engelman JA, Zejnullahu K, Mitsudomi T, et al. (2007) MET amplification leads to
l l
gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-43
42. Onozato R, Kosaka T, Kuwano H, et al. (2009) Activation of MET by gene amplification
or by splice mutations deleting the juxtamembrane domain in primary resected lung
cancers. J Thorac Oncol 4: 5-11
22. Van Cutsem E, Sobrero AF, Siena S, et al. (2012) Phase III CORRECT trial of regorafenib
in metastatic colorectal cancer (mCRC). ASCO Annual Meeting, Chicago, 01-05 juin
23. Van Cutsem E, Tabernero J, Lakomy R, et al. (2012) Addition of Aflibercept to Fluorouracil,
Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients
With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen.
J Clin Oncol 30: 3499-506
24. Tonon G, Wong KK, Maulik G, et al. (2005) High-resolution genomic profiles of human
lung cancer. Proc Natl Acad Sci U S A 102: 9625-30
25. Ding L, Getz G, Wheeler DA, et al. (2008) Somatic mutations affect key pathways in lung
l l
adenocarcinoma. Nature 455: 1069-75
26. Rauch TA, Zhong X, Wu X, et al. (2008) High-resolution mapping of DNA hypermethylation
and hypomethylation in lung cancer. Proc Natl Acad Sci U S A 105: 252-7
27. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet
Oncol 12: 175-80
28. Tang X, Shigematsu H, Bekele BN, et al. (2005) EGFR tyrosine kinase domain mutations
l l
are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer
Res 65: 7568-72
29. Kobayashi S, Boggon TJ, Dayaram T, et al. (2005) EGFR mutation and resistance of
l l
non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-92
30. Massarelli E, Varella-Garcia M, Tang X, et al. (2007) KRAS mutation is an important
l l
predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase
inhibitors in non-small-cell lung cancer. Clin Cancer Res 13: 2890-6
31. Soda M, Choi YL, Enomoto M, et al. (2007) Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature 448: 561-6
32. Shaw AT, Yeap BY, Mino-Kenudson M, et al. (2009) Clinical features and outcome
of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:
4247-53
33. Shaw AT, Yeap BY, Solomon BJ, et al. (2011) Effect of crizotinib on overall survival in
l l
patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a
retrospective analysis. Lancet Oncol 12: 1004-12
34. Bergethon K, Shaw AT, Ou SH, et al. (2012) ROS1 rearrangements define a unique
l l
molecular class of lung cancers. J Clin Oncol 30: 863-70
35. Stephens P, Hunter C, Bignell G, et al. (2004) Lung cancer: intragenic ERBB2 kinase
l l
mutations in tumours. Nature 431: 525-6
36. Arcila ME, Chaft JE, Nafa K, et al. (2012) Prevalence, clinicopathologic associations, and
l l
molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Clin Cancer Res 18: 4910-8
37. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. (2005) Increased HER2 gene copy
l l
number is associated with response to gefitinib therapy in epidermal growth factor
receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23: 5007-18
38. Paik PK, Arcila ME, Fara M, et al. (2011) Clinical characteristics of patients with lung
l l
adenocarcinomas harboring BRAF mutations. J Clin Oncol 29: 2046-51
39. Yamamoto H, Shigematsu H, Nomura M, et al. (2008) PIK3CA mutations and copy
number gains in human lung cancers. Cancer Res 68: 6913-21
40. Cappuzzo F, Marchetti A, Skokan M, et al. (2009) Increased MET gene copy number
negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin
Oncol 27: 1667-74
41. Engelman JA, Zejnullahu K, Mitsudomi T, et al. (2007) MET amplification leads to
l l
gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-43
42. Onozato R, Kosaka T, Kuwano H, et al. (2009) Activation of MET by gene amplification
or by splice mutations deleting the juxtamembrane domain in primary resected lung
cancers. J Thorac Oncol 4: 5-11